new morningstar report

I got an update on CXS vis Westpac Broking from Morningstar saying high risk buy. Sorry can't post due to copyright but for those who can access it's worth a read.


http://preview.morningstar.com.au/Stocks

A snip though referring to the Hospira deal

"The deal is better than we expected and more than validates our valuation which we increase from $1.40 to $1.60. This assumes peak patient numbers in the T3151 mutation niche of 2,000 by 2013, a drug price of A$65,000, a discount rate of 12%, and 10-year drug life."